IL-17A and TNF-α as potential biomarkers for acute respiratory distress syndrome and mortality in patients with obesity and COVID-19

Copyright © 2020. Published by Elsevier Ltd..

Coronavirus disease 2019 (COVID-19) was declared a pandemic and international health emergency by the World Health Organization. Patients with obesity with COVID-19 are 7 times more likely to need invasive mechanical ventilation than are patients without obesity (OR 7.36; 95% CI: 1.63-33.14, p = 0.021). Acute respiratory distress syndrome (ARDS) is one of the main causes of death related to COVID-19 and is triggered by a cytokine storm that damages the respiratory epithelium. Interleukins that cause the chronic low-grade inflammatory state of obesity, such as interleukin (IL)-1β, IL-6, monocyte chemoattractant peptide (MCP)-1, and, in particular, IL-17A and tumour necrosis factor alpha (TNF-α), also play very important roles in lung damage in ARDS. Therefore, obesity is associated with an immune state favourable to a cytokine storm. Our hypothesis is that serum concentrations of TNF-α and IL-17A are more elevated in patients with obesity and COVID-19, and consequently, they have a greater probability of developing ARDS and death. The immunobiology of IL-17A and TNF-α opens a new fascinating field of research for COVID-19.

Medienart:

E-Artikel

Erscheinungsjahr:

2020

Erschienen:

2020

Enthalten in:

Zur Gesamtaufnahme - volume:144

Enthalten in:

Medical hypotheses - 144(2020) vom: 05. Nov., Seite 109935

Sprache:

Englisch

Beteiligte Personen:

Leija-Martínez, José J [VerfasserIn]
Huang, Fengyang [VerfasserIn]
Del-Río-Navarro, Blanca E [VerfasserIn]
Sanchéz-Muñoz, Fausto [VerfasserIn]
Muñoz-Hernández, Onofre [VerfasserIn]
Giacoman-Martínez, Abraham [VerfasserIn]
Hall-Mondragon, Margareth S [VerfasserIn]
Espinosa-Velazquez, Dario [VerfasserIn]

Links:

Volltext

Themen:

Acute respiratory distress syndrome
Biomarkers
COVID-19
IL-17A
IL17A protein, human
Interleukin-17
Journal Article
Mortality
Obesity
TNF protein, human
Tumor Necrosis Factor-alpha
Tumour necrosis factor-alpha

Anmerkungen:

Date Completed 04.12.2020

Date Revised 10.01.2021

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1016/j.mehy.2020.109935

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM313704961